PTX contributed another potential advantage against COVID-19 severity, as seen in a reduction in IL-6, an important marker of cytokine storm syndrome, and C-reactive protein (CRP), according to a prospective trial by Chavarra et al. that involved 110 COVID-19 patients treated with normal therapy in combination with PTX and numerous antioxidants [40]; this agreed with our results as IL-6 decreased from 47.2 pg/mL. This evidence concerns the gene IL6 and COVID-19.